Subscribe for the newsletter
Mobile Navigation
Subscribe for the Newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Directory
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Rafael Pharmaceuticals, Inc.
Sort By
Newest First
1 / 1
1 / 1
Sign in
Fast Track
Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Pancreatic Cancer
Rafael Pharmaceuticals, Inc.
PR-M11-20-012
Nov 12, 2020
